Emmaus Life Sciences
OTC: EMMATorrance, US · Delaware corporation
Emmaus Life Sciences is a pharmaceutical company that develops and commercializes Endari (prescription-grade L-glutamine oral powder), an FDA-approved treatment for sickle cell disease, and pursues additional indications such as diverticulosis. The company sells and seeks marketing authorization for its products in the United States and internationally, including the Middle East and North Africa region.
BiotechHealthtechMedical Devices
Founders & leadership
YN
Yutaka NiiharaFormer Chairman & CEO
KK
Kurt KrugerExecutive
WL
Willis LeeExecutive
LT
Lan TranExecutive
YN
Yasushi NagasakiExecutive
WC
Willis C. LeeChief Executive Officer
Board
RD
Robert DickeyBoard director
MO
Masaharu OsatoBoard director
WP
Wei Peu ZenBoard director
IZ
Ian ZwickerBoard director
Reported raises · per SEC filings
Form D private placements$36.5M disclosed across 4 rounds · 2016–2019
▶$2.6MraisedApr 2019 · 7 investors · PharmaceuticalsRule 506(c)
▶$2.6MraisedApr 2019 · 7 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Yutaka NiiharaExecutive Officer, Director
- Kurt KrugerExecutive Officer
- Willis LeeExecutive Officer, Director
- Lan TranExecutive Officer
- Yasushi NagasakiExecutive Officer
- Robert DickeyDirector
- Masaharu OsatoDirector
- Wei Peu ZenDirector
- Ian ZwickerDirector
- Amount sold
- $2.6M
- Sales commissions
- $600K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$12.2MraisedNov 2018 · 18 investors · PharmaceuticalsRule 506(c)
▶$12.2MraisedNov 2018 · 18 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Yutaka NiiharaExecutive Officer, Director
- Masaharu OsatoDirector
- Willis LeeExecutive Officer, Director
- Wei Peu ZenDirector
- Robert DickeyDirector
- Lan TranExecutive Officer
- Kurt KrugerExecutive Officer
- Ian ZwickerDirector
- Yasushi NagasakiExecutive Officer
- Offering amount
- $12.2M
- Amount sold
- $12.2M
- Sales commissions
- $610K
- Placement agents
- T.R. Winston & Company, LLC
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$20MraisedOct 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$20MraisedOct 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lan T TranExecutive Officer
- Yutaka NiiharaExecutive Officer, Director
- Jon KuwaharaDirector
- Peter B LudlumExecutive Officer
- Ian ZwickerDirector
- Willis C LeeExecutive Officer, Director
- Yasushi NagasakiExecutive Officer
- Masaharu OsatoDirector
- Offering amount
- $20M
- Amount sold
- $20M
- Finders' fees
- $600K
- Proceeds to insiders
- $1M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedJan 2016 · PharmaceuticalsRule 506(b)
▶$1.7MraisedJan 2016 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jon KuwaharaDirector
- Willis C LeeExecutive Officer, Director
- Ian ZwickerDirector
- Lan T TranExecutive Officer
- Yutaka NiiharaExecutive Officer, Director
- Yasushi NagasakiExecutive Officer
- Masaharu OsatoDirector
- Peter B LudlumExecutive Officer
- Offering amount
- $40M
- Amount sold
- $1.7M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapMedscape43 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Amicus Therapeutics33 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Agenus30 shared keywords
Companies competing with Emmaus Life Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Emmaus Life Sciences do?
- Emmaus Life Sciences is a pharmaceutical company that develops and commercializes Endari (prescription-grade L-glutamine oral powder), an FDA-approved treatment for sickle cell disease, and pursues additional indications such as diverticulosis. The company sells and seeks marketing authorization for its products in the United States and internationally, including the Middle East and North Africa region.
- Who founded Emmaus Life Sciences?
- Emmaus Life Sciences was founded by Yutaka Niihara.
- How much funding has Emmaus Life Sciences raised?
- Emmaus Life Sciences has disclosed $36.5M raised across 4 rounds.
- Where is Emmaus Life Sciences headquartered?
- Emmaus Life Sciences is headquartered in Torrance, US.